Meridian Activation Remedy System for Parkinson's Disease

In this study, the investigators aim to evaluate the clinical efficacy and cost-effectiveness of MARS-PD. Conventional, usual care will be used as the comparator because this trial aims to assess the add-on effect of MARS-PD. The investigators hypothesize that the complex therapy will relieve motor and nonmotor symptoms, improve gait performance, and enhance neuroplasticity in PD patients, and will be safe and cost-effective.

Inclusion Criteria:45 to 75 years of agePatients with PD, diagnosed according to the United Kingdom Parkinson's Diseases Society Brain Bank CriteriaHoehn and Yahr scale stage I to IIIPatients who have voluntarily decided to participate in the clinical study and signed the informed consent formExclusion Criteria:Clinically unstable patients (e.g., elevated aspartate transaminase (AST) or alanine aminotransferase (ALT) more than three-fold the upper limit of normal in the research institute's laboratory, heart failure, respiratory failure, etc.)Patients who are planning to undergo deep brain stimulation within the study periodPregnant or lactating womenPatients with MMSE-K (Mini-Mental State Exam) score of 18 or lessIf there has been a change in the dosage of antiparkinsonian drugs (e.g., L-dopa, COMT (catechol-O-methyltransferase) inhibitor, Dopamine agonist, MAO-B (monoamine oxidase B) inhibitor, etc.) according to a doctor's prescription within the last 4 weeks prior to enrollmentPatients who are receiving manual therapy, exercise therapy, or rehabilitation therapy for Parkinson's disease according to a doctor's prescription within the last 4 weeks prior to enrollment, or are planning to receive such therapy within the study periodPatients who are not suitable for participation in this clinical study according to the judgment of the researcher